RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo.
Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的结果揭示了结直肠癌(CRC)肿瘤的免疫学特征:免疫原性(MSI-H)与免疫逃逸机制(HLA 下调)在疾病早期阶段有利于 NK 细胞免疫监视。
结直肠癌(CRC)具有异质性,其突变谱和肿瘤微环境组成不同,进而影响肿瘤进展和治疗应答。化疗耐药、免疫原性差的CRC仍是治疗难题;以生物标志物为指导制定新策略,有助于患者分层和治疗。异体NK细胞转输是治疗化疗耐药且免疫原性差CRC的一种替代选择。
研究通过转录组学和免疫组化分析人CRC样本中的NK细胞相关免疫标志物,并评估其与肿瘤进展及总生存期的关系。采用细胞因子和饲养细胞联合方案扩增异体NK细胞,在体内外分析其抗肿瘤能力,并结合CRC突变状态及调节NK细胞活性的免疫检查点(IC)受体配体表达进行评估。
在低分期(II期)微卫星高度不稳定(MSI-H)CRC患者中,HLA-I下调和NK细胞浸润与总生存期较长相关,提示HLA-I可能是预后生物标志物,患者可能从NK细胞免疫疗法中获益。活化异体NK细胞能够清除CRC细胞培养物,该作用不受PD-1和TIM-3限制,但会受到HLA-I表达影响。体内实验确认该疗法对HLA阳性和HLA阴性CRC细胞系均有效。联合给予帕博利珠单抗未能增强肿瘤控制。
研究揭示了CRC肿瘤的一种免疫特征:在疾病早期,MSI-H免疫原性和HLA下调介导的免疫逃逸机制有利于NK细胞免疫监视。研究还证明,异体NK细胞疗法可靶向带有不良预后突变的肿瘤,且不受T细胞相关抑制性免疫检查点配体表达影响。总体而言,该研究为CRC新型分层策略及NK细胞疗法提供了依据。
Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC.
NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity.
HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA + and HLA - CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control.
Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。